<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbott laboratories, withdrawal of drug registration application</td>
<td>199–204</td>
</tr>
<tr>
<td>Competition Act of Thailand, Section 25(3) complaint 200–202</td>
<td></td>
</tr>
<tr>
<td>Competition Act of Thailand, Section 28 complaint 202</td>
<td></td>
</tr>
<tr>
<td>abuse of a dominant position and deception by a right holder</td>
<td>115–116</td>
</tr>
<tr>
<td>and developed countries 71–77</td>
<td></td>
</tr>
<tr>
<td>excessive pricing 299</td>
<td></td>
</tr>
<tr>
<td>market share 225</td>
<td></td>
</tr>
<tr>
<td>in South Africa 182</td>
<td></td>
</tr>
<tr>
<td>in Vietnam 223–226, 231</td>
<td></td>
</tr>
<tr>
<td>Agreement on Measures to Discourage the Importation of Counterfeit</td>
<td></td>
</tr>
<tr>
<td>Goods (1982) 1</td>
<td></td>
</tr>
<tr>
<td>Agreement on Safeguards, Article 11.3</td>
<td>279–280</td>
</tr>
<tr>
<td>Agreement on Trade-Related Aspects of Intellectual Property Rights see</td>
<td></td>
</tr>
<tr>
<td>TRIPS Agreement</td>
<td></td>
</tr>
<tr>
<td>allocative efficiency, IPRs and competition law</td>
<td>34</td>
</tr>
<tr>
<td>Annel Draft, TRIPS Agreement 52</td>
<td></td>
</tr>
<tr>
<td>anti-commons, tragedy of 21</td>
<td>21</td>
</tr>
<tr>
<td>anti-competitive agreements, per se rule and rule of reason 68–71</td>
<td></td>
</tr>
<tr>
<td>anti-competitive non-price practices</td>
<td></td>
</tr>
<tr>
<td>exclusivity in technology transfer agreements 99–104</td>
<td></td>
</tr>
<tr>
<td>grantbacks 90–92</td>
<td></td>
</tr>
<tr>
<td>non-challenge clauses 97–99</td>
<td></td>
</tr>
<tr>
<td>tying and package licensing 92–97</td>
<td></td>
</tr>
<tr>
<td>anti-competitive practices</td>
<td></td>
</tr>
<tr>
<td>compulsory licensing 46–47, 51</td>
<td></td>
</tr>
<tr>
<td>developed countries restrictions on product prices 86–90</td>
<td></td>
</tr>
<tr>
<td>royalty concerns 78–86</td>
<td></td>
</tr>
<tr>
<td>free-riding, elimination 12, 89</td>
<td></td>
</tr>
<tr>
<td>interpretation of term 46</td>
<td></td>
</tr>
<tr>
<td>non-price see anti-competitive non-price practices prices 77–90</td>
<td></td>
</tr>
<tr>
<td>antitrust and IP law US</td>
<td></td>
</tr>
<tr>
<td>antitrust law as lex specialis</td>
<td>118</td>
</tr>
<tr>
<td>Antitrust–IP Guidelines (1995)</td>
<td>Section 1.0 36, 63</td>
</tr>
<tr>
<td>Antitrust–IP Guidelines (1995)</td>
<td>Section 2.3 71</td>
</tr>
<tr>
<td>Antitrust–IP Guidelines (1995)</td>
<td>Section 3.4 70, 71</td>
</tr>
<tr>
<td>Antitrust–IP Guidelines (1995)</td>
<td>Section 5.3 95</td>
</tr>
<tr>
<td>as complementary 63</td>
<td></td>
</tr>
<tr>
<td>development of IP-antitrust law</td>
<td></td>
</tr>
<tr>
<td>intersection 59–64</td>
<td></td>
</tr>
<tr>
<td>favouring of antitrust law over IPRs</td>
<td>62</td>
</tr>
<tr>
<td>favouring of IP law over antitrust law</td>
<td>60, 61</td>
</tr>
<tr>
<td>licence containing price-fixing clause compatible with 60</td>
<td></td>
</tr>
<tr>
<td>misuse doctrine 61–62</td>
<td></td>
</tr>
<tr>
<td>Nine No-NoS, as violation of antitrust law</td>
<td></td>
</tr>
<tr>
<td>overlapping of antitrust law with regulatory statutes 113</td>
<td></td>
</tr>
<tr>
<td>APEC (Asia Pacific Economic Cooperation Forum), Vietnamese membership</td>
<td>213</td>
</tr>
<tr>
<td>appropriateness requirement, competition law and TRIPS Agreement 50,</td>
<td></td>
</tr>
<tr>
<td>Agreement 51</td>
<td></td>
</tr>
<tr>
<td>Argentina</td>
<td></td>
</tr>
<tr>
<td>Argentina-US mutually agreed solutions 247–250</td>
<td></td>
</tr>
<tr>
<td>Law on Patents and Utility Models 249</td>
<td></td>
</tr>
<tr>
<td>Article 44 247, 248</td>
<td></td>
</tr>
</tbody>
</table>
ASEAN (Association of South East Asian Countries), Vietnamese membership 213

Berne Convention for the Protection of Literary and Artistic Works
Article 5.5 and TRIPS Agreement 2
Vietnam a party to 216 bilateral agreements
and TRIPS-plus standards 251–253 and Vietnam 213 biotechnological inventions, Directive 98/44/EEC on legal protection 146
BIT (Bilateral Investment Treaty), 2004
Article 6.2 253
Article 8.3(b)(ii) 252
‘black’/’no-no’ clauses, licensing agreements 66
Brussels Draft, TRIPS Agreement 46, 52

CARIFORUM states, negotiations with EU (2008) 284 cases discussed 209–210
AOIP/Byrard 66, 84
Argentina – Measures Affecting the Export of Bovine Hide and the Import of Finished Leather 47, 279
Arizona v. Maricopa County Medical Society 68, 69, 70
Aro Manufacturing Co. v. Convertible Top Replacement Co. 138, 139
Aspen Skiing Company v. Aspen Highlands Skiing Corp. 107, 108
Automatic Radio Manufacturing Co. v Hazeltine Research 84–85
Botino Boats, Inc. v. Thunder Craft Boats, Inc. 17, 38
Bousois/Interpane 84, 92
British Airways v. Commission 76, 77
Broadcom v. Qualcomm 115, 116
Brulotte v. Thys Co. 79, 82, 83
Canada – Patent Protection of Pharmaceutical Products 23, 29
Centrafarm v. Sterling Drug 17, 145

Coditel v. Ciné-Vog Films 66, 101
Commercial Solvents (Istituto Chemioterapico Italiano and Commercial Solvents v. Commission) 76, 119, 120, 126
Consten & Grundig v. Commission 64, 65–66, 100, 150
Continental T. V., Inc v. GTE Sylvania Inc. 69, 100
Credit Suisse Securities (USA) LLC v. Billing 109, 113
Davidson Rubber Co. 66, 98, 100
Dawson Chemical Co. v Rohm and Hass Co. 63, 109
Deutsche Grammophon v. Metro 65, 79, 145
Deutsche Telekom v. Commission 81, 113
Develey v OHIM 8–9
Eastman Kodak Co. v. Image Technical Services, Inc. 93, 94, 95, 96
eBay Inc. v. MercExchange L.L.C. 109, 110, 111, 118–119
EC – Asbestos 50, 51
EC – Protection of Trademarks and Geographical Indications for Agricultural Products and Foodstuffs 5, 249
Fabbrica italiana accumulatori motocarri Montecchio SpA v Council (FIAMM) 9, 10
France Télécom v. Commission 74, 224
FTC v Indiana Federation of Dentists 69, 70
General Talking Pictures Corp. v. Western Electric Co. 133, 134
Glaxo Wellcome and Others v. National Association of Pharmaceutical Wholesalers and Others 182, 183
Hazel Tau v. GSK & BI 180, 183, 184–188, 189, 192, 195, 197, 198
Illinois Tool Works Inc. v. Independent Ink, Inc. 63, 95, 106, 208
<table>
<thead>
<tr>
<th>Citation</th>
<th>Pages/References</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMS Health GmbH &amp; Co. OHG v. NDC Health GmbH &amp; Co. KG</td>
<td>120, 122, 124, 125, 126, 127, 192</td>
</tr>
<tr>
<td>Antitrust Litigation, In re</td>
<td>109</td>
</tr>
<tr>
<td>India – Patents Protection for Pharmaceutical and Agricultural Chemical Products</td>
<td>52</td>
</tr>
<tr>
<td>Innogenetics, N.V. v. Abbott Laboratories</td>
<td>110, 111</td>
</tr>
<tr>
<td>Jefferson Parish Hospital District No. 2 v. Hyde</td>
<td>63, 94, 95</td>
</tr>
<tr>
<td>Kanal 5 Ltd, TV 4 AB v. Föreningen Svenska Tonsättareerna</td>
<td>74, 85</td>
</tr>
<tr>
<td>Keeler v. Standard Folding Bed</td>
<td>132, 133</td>
</tr>
<tr>
<td>Kelo v. City of New London</td>
<td>22, 112</td>
</tr>
<tr>
<td>Kewanee Oil Company v. Bicron Corporation</td>
<td>16, 17</td>
</tr>
<tr>
<td>Kodak (Image Technical Services, Inc. v. Eastman Kodak Co.)</td>
<td>109, 114, 117, 195, 221, 225</td>
</tr>
<tr>
<td>Ladbroke (Tiercé Ladbroke SA v. Commission)</td>
<td>120, 125–126, 151</td>
</tr>
<tr>
<td>Laserdisken ApS v. Kulturministeriet</td>
<td>17, 146</td>
</tr>
<tr>
<td>Lear, Inc. v. Adkins</td>
<td>84, 97, 98</td>
</tr>
<tr>
<td>Leegin Creative Leather Products, Inc. v. PSKS, Inc.</td>
<td>68, 69, 88, 89</td>
</tr>
<tr>
<td>Linkline (Pacific Bell Telephone Co. v. Linkline Communications, Inc.)</td>
<td>72, 79, 81, 106</td>
</tr>
<tr>
<td>Mallinckrodt, Inc. v. Medipart, Inc.</td>
<td>137, 138, 139, 141, 150, 153</td>
</tr>
<tr>
<td>Medellin v. Texas</td>
<td>8, 11</td>
</tr>
<tr>
<td>MedImmune, Inc. v. Genentech, Inc.</td>
<td>98, 118</td>
</tr>
<tr>
<td>Microsoft v. Commission</td>
<td>10, 118, 155, 156, 158–159, 283, 301</td>
</tr>
<tr>
<td>contractual restrictions on downstream purchasers</td>
<td>153–154</td>
</tr>
<tr>
<td>monopolization or abuse of a dominant position (two-pronged test)</td>
<td>73, 74, 77</td>
</tr>
<tr>
<td>refusal to license</td>
<td>122, 125, 126, 128, 192</td>
</tr>
<tr>
<td>tying and package licensing</td>
<td>93, 94, 95, 96, 97</td>
</tr>
<tr>
<td>Monsanto v. McFarling</td>
<td>61, 140</td>
</tr>
<tr>
<td>Motion Picture Patents Co. v. Universal Film Manufacturing Co.</td>
<td>61, 135</td>
</tr>
<tr>
<td>National Collegiate Athletic Association v. Board of Regents of the University of Oklahoma (NCAA)</td>
<td>70, 104</td>
</tr>
<tr>
<td>National Society of Professional Engineers v. US</td>
<td>69</td>
</tr>
<tr>
<td>Nintendo of America (Atari Games Corp. v. Nintendo of America, Inc.)</td>
<td>63, 104–105</td>
</tr>
<tr>
<td>Northern Pacific Railway Co. v. US</td>
<td>69, 93</td>
</tr>
<tr>
<td>Nungesser KG &amp; Kurt Eisele v. Commission</td>
<td>66, 100</td>
</tr>
<tr>
<td>Oscar Bronner v. Mediaprint</td>
<td>120, 126, 173, 183</td>
</tr>
<tr>
<td>Paice LLC v. Toyota Motor Corp.</td>
<td>110–111</td>
</tr>
<tr>
<td>Pedro IV Servicios v. Total</td>
<td>89–90</td>
</tr>
<tr>
<td>Prino Corp. v. ITC</td>
<td>61, 101</td>
</tr>
<tr>
<td>Productores de Musica de España (Promusicae) v. Telefonica de España SAU</td>
<td>17</td>
</tr>
<tr>
<td>Qualcomm v. Broadcom</td>
<td>115, 116</td>
</tr>
<tr>
<td>Quanta Computer, Inc. v. LG Electronics, Inc.</td>
<td>119</td>
</tr>
<tr>
<td>and Federal Circuit judgments</td>
<td>136–145</td>
</tr>
<tr>
<td>implications 129–136</td>
<td></td>
</tr>
<tr>
<td>McFarling II and ‘single crop only’</td>
<td>140–145</td>
</tr>
<tr>
<td>prism of 132–136, 142, 145, 150, 154</td>
<td></td>
</tr>
<tr>
<td>‘single use only’ restriction</td>
<td>136–137, 138, 139</td>
</tr>
</tbody>
</table>

Tu Thanh Nguyen - 9781849805445
Downloaded from Elgar Online at 11/11/2021 03:10:30AM
via free access
Radio Telefix Eireann (RTE) and Independent Television Publications Ltd (ITP) v. Commission (Magill) 120, 124, 125, 126

and copyright 17

four-factor test 127

IP-competition law intersection, development 65

refusal to license 121–127

Rambus Inc. v. FTC 44, 45, 73, 115

Raymond & Co. and Nagoya Rubber Co. Ltd 66, 92

Renault (Consorzio italiano della componentistica di ricambio per autoveicoli and Maxisar v. Régie nationale des usines Renault) 80, 120–121, 125, 126

Smith Kline & French Laboratories, Ltd. v. Court of Appeals 171, 193

Sot. Lelos kai Sia EE v. GlaxoSmithKline AEVE 76, 101, 113, 120, 129, 152, 153

Spectrum Sports, Inc. v. McQuillan 72, 73

State Oil Co. v. Khan 68, 69, 88, 89

Syfai v. GSK 101, 152

TAC v. BMS 181, 183, 188, 192, 196


THP v. VBL 234, 238–242

UCB 201–202

United Brands v. Commission 76, 80, 120

US – Havana Club 2, 5, 49

US – Section 110(5) of the US Copyright Act 23, 155

US Philips Corp. v. ITC 71, 93, 96, 97, 106, 207, 208, 211

US v. Aluminium Co. of America 72, 257

US v. Dentsply Int’l, Inc 104, 159

US v. General Electric Co. 60, 86–87, 88, 135

US v. Joint-Traffic Ass’n 68, 69

US v. Line Material Co. 87, 88

US v. Microsoft Corp (Microsoft I) 72, 86, 103

US v. Microsoft Corp (Microsoft III) 38, 103, 115–116, 136, 177

monopolization or abuse of a dominant position (two-pronged test) 72–73, 75, 76, 77

tyling and package licensing 94, 96

US v. Univis Lens 130, 148

Vallal Peruman & Dileep Singh Bhuria v. Godfrey Phillips (India) Ltd 167–168

Van den Bergh Foods v. Commission 71, 73

Verizon Communications Inc. v. Law Offices of Curtis v. Trinko 72, 75, 79, 81, 106–109, 118

post-Trinko development 109–114

Volvo (AB Volvo v. Erik Veng (UK) Ltd) 80, 120–121, 125, 126

Weyerhaeuser Co. v. Ross-Simmons Hardware Lumber Co., Inc. 73, 115

Windsurfing International Inc. v. Commission 66, 85, 99

Xerox (SCM Corp. v. Xerox Corp.) 114, 115, 117, 118, 143, 144

Yassin Abdullah Kadi v. Council and Commission 10, 11

Zenith Radio Corp. v. Council and Commission 10, 11

Zuellig Pharma 237, 238

see also Philips’ Taiwan Package licensing case

CDIP (Committee on Development and Intellectual Property), WIPO 275

Charter of Fundamental Rights (EU), on IP protection 17

Chicago School, on leverage theory 95

Chinese Anti-Monopoly Law 250–251, 263

Article 55 168, 169, 250

Clayton Act (1914), US, Section 7 59

Coase theorem, economic efficiency 19

Colgate doctrine, refusal to license in US 108

collective consumption good, IP 12

Commission on Intellectual Property Rights 53
Community exhaustion placed on market by patent holder or with her consent 147–150
principle of 145–146
territoriality 146–147
Competition Act of Thailand
Section 25(1) 203
Section 25(3) complaint 200, 200–202
Section 28 complaint 200, 202
Section 29 203
competition authorities
cooperation with IP authorities in developing countries 294
international cooperation between 260–267
negative comity agreements 264
positive comity agreements 264–265
remedies 261
technical 262–263
TRIPS Agreement 261–262
IPRs and competition law 36
lack of cooperation with IP authorities 246–247
Competition Council, Vietnam 219
competition culture, absence of in developing countries 246
competition law
alternatives/challenges 256–276
application to developing countries see developing countries
application to technology transfer in developed countries see developed countries, application of competition law to technology transfer in developing countries see developing countries
global context 256–285
development, innovation and systemic perspectives 56
enforcement outsourcing 256–260
harmonization through international forums 267–276
ICN 273–274
OECD 271–272
UNCTAD 272–273
WIPO and WHO 274–275
WTO 267–271
international cooperation between competition authorities 260–267
IPR-related, in developing countries 292–293
obligations 48–52
overview of applications and disposition 52–57
rights 45–48
and TRIPS Agreement 42–57
flexibilities 54, 55, 56
interpretation 45–52
obligations 48–52
prior to 39–42
rights 45–48
ultimate objective 77
in Vietnam 230–233
competition rules, IPRs and competition law 32–39
competition welfare 34
compulsory licensing see licensing
concerted actions, Sherman Act on 59
Confederation of Societies of Authors and Composers (CISAC), exclusivity clause 102
consequentialist theory, justifications for IPRs 15
consistency requirement, competition law and TRIPS Agreement 51
consumer welfare 34, 36
Credit Suisse Securities (USA) LLC v. Billing 109, 113
Croatia, Microsoft Croatia tying case 179–180, 254, 259
de jure or de facto discrimination, evaluation 5
developed countries, application of competition law to technology transfer
anti-competitive agreements 68–71
anti-competitive non-price practices exclusivity in technology transfer agreements 99–104
grantbacks 90–92
non-challenge clauses 97–99
tyling and package licensing 92–97

Tu Thanh Nguyen - 9781849805445
Downloaded from Elgar Online at 11/11/2021 03:10:30AM via free access
anti-competitive price practices 77–90
restrictions on product prices 86–90
royalty concerns 78–86
background 59–77
compatibility with TRIPS Agreement 155–159
arguments against TRIPS compatibility 155–157
arguments for TRIPS compatibility 157–159
contractual restrictions on downstream purchasers 128–154
EU perspective 145–154
US perspective 129–145
EU, development of IP-competition law intersection 64–68
monopolization or abuse of a dominant position (two-pronged test) 71–77
principles 68–77
refusal to transfer technology 105–128
refusal to license in US 106–119
US, development of IP-antitrust law intersection 59–64
developing countries
Abbott laboratories, withdrawal of drug registration application (in Thailand) 199–204
Competition Act of Thailand, Section 25(3) complaint 200–202
Competition Act of Thailand, Section 28 complaint 202
absence of competition culture in 246
anti-competitive practices, concerns about adverse effects 42
application of technology transfer to competition law
Abbott laboratories, withdrawal of drug registration application (in Thailand) 199–204
background 161–174
bilateral agreements and TRIPS-plus standards 250–251
current models 166–174
Microsoft tying cases 174–180, 254
normative models 169–174
Philips’ Taiwan Package licensing case 204–212
refusal to license pharmaceutical patents 180–199
Vietnam, case study 212–243
Argentina-US mutually agreed solutions 247–250
‘compassion and good sense’, right to 289
competition law and TRIPS Agreement 53
current models, substantive law
hybrid model 174
laissez-faire 169–170
normative 169–174
quasi per se prohibition model 170–171
simple rule of reason model 172–173
‘development’ test 163
domestic competition law, enacting 254
downstream purchasers, use restrictions on 299
‘ecology of innovation’ needed to build 300
excessive pricing 298–299
external obstacles
Anti-Monopoly Law of China, EC communications 250–251
Argentina-US mutually agreed solutions 247–250
bilateral agreements and TRIPS-plus standards 251–253
general implications for 290–296
cooperation between competition authorities and IP authorities 294
importance of IPR-related competition law in technology transfer and economic growth 292–293
international cooperation in enforcement of IPR-related competition law 294–295
tailoring and enforcing domestic IPR-related competition law to suit particular socio-economic contexts 293
implications for 286–302
general 290–296
innovation-oriented rules, persuaded to accept 263
internal obstacles
absence of competition culture 246
deficiency of legislation 244–246
lack of capacity 244
lack of cooperation between
competition authorities and
IP authorities 246–247
lack of capacity obstacle 244
lack of cooperation between
competition authorities and IP
authorities 246–247
legislation, deficiency 244–246
Microsoft tying cases 174–180
Microsoft Croatia 179–180, 254,
259
Microsoft Korea 175–178, 180,
254
Microsoft Taiwan 178–179, 180,
254
obstacles for
external 247–253
internal 244–247
pharmaceutical patents cases, refusal
to license 180–199
Aluvia 199–200, 201
application of competition law
under pressure of publicity 198
background 180–184
dominant position of a right
holder 195–196
effects of IPR-related competition
law application 192–195
Hazel Tau v. GSK & BI 180, 183,
184–188, 189, 192, 195,
197, 198
HIV/AIDS treatment 184, 186,
187, 200
IPR-related excessive pricing and
refusal to license under
competition law 196–198
Kaletra 199, 200
remedies against anti-competitive
pricing and refusal to
license 198–199
TAC v. BMS 181, 183, 188, 192,
196
TAC v. MSD v Merck 181,
183–184, 189–192, 194,
195, 197–198
world sales of products 193
Philips’ Taiwan Package licensing
case 204–212
background 204–206
other cases involved 206–210
refusal to license 297–298
specific cases (competition law,
application of technology
transfer to)
Abbott laboratories, withdrawal of
drug registration
application (in Thailand)
199–204
Microsoft tying cases 174–180,
254
Philips’ Taiwan Package licensing
case 204–212
refusal to license pharmaceutical
patents 180–199
specific implications for 296–299
strengthening of IP regimes 26
and TRIPS Agreement 4, 27, 287
tyling 299
Vietnam, case study
background 212–226
technology transfer-related
competition law issues
226–242
see also LDCs (least-developed
countries)
disclosure thesis, IP protection 14, 15
dispute settlement 280–283
trade policy review mechanism 282
Doha Declaration on TRIPS Agreement
and Public Health (2001) 150,
283
adoption of 277
compulsory licensing of patented
pharmaceuticals under 292
Decision on Implementation of
Paragraph 6, adoption 31
medicines, access to 186
technology transfer-oriented provisions 29, 30
doi moi process, Vietnam 213
dominant position
abuse of see abuse of a dominant position
of right holder, in South Africa 195–196
single-enterprise 226
in Thailand 200
downstream purchasers
contractual restrictions on
EU perspective 145–154
patent exhaustion doctrine 131, 135, 136
US perspective 129–145
use restrictions on 299
DSU (Dispute Settlement Understanding)
appropriateness requirement 50
and Argentina 249
Articles
Article 19 9
Article 22 9
Article 26 52
and IPRs 2
Dunkel Draft, TRIPS Agreement 52
dynamic efficiency, IPRs and competition law 33, 34, 35
Ebay Inc. v. MercExchange L.L.C. 109, 110, 118–119
four-factor test 111
EC Treaty
Article 3.1(g) 64, 145
Article 28 145
Article 30 64, 145
Article 81 36, 64, 65, 102, 157, 221, 259
Article 81(1) 65, 66, 70, 71, 84, 90, 92, 99, 101, 219, 221
Article 81(3) 70–71, 77, 89, 90, 92, 101
Article 82 34, 64, 65, 75, 77, 81–82, 85, 92, 93, 97, 102, 104, 120, 121, 124, 125, 127, 128, 153, 155, 156, 157, 224, 259
types of abusive conduct under 74
Article 82(a) 79, 82

Article 85(3) 66
Article 295 64–65
‘ecology of innovation’, defined 300
economic efficiency
Coase theorem 19
IPRs and competition law 33–34
effect doctrine, enforcement outsourcing, 257, 258
enforcement
international cooperation 294–295
of IPRs, under property rules 19–20
outsourcing 256–260
over-enforcement/under-enforcement 276–278
rare nature of 244
TRIPS Agreement rules 2
enterprise, terminology 218
essential facility doctrine
pharmaceutical patents cases 182, 183
refusal to license in US 108
EU see European Union (EU)
European Convention for the Protection of Human Rights and Fundamental Freedoms (1950), on IP protection 13
European Court of Human Rights, on IP protection 13
European Court of Justice (ECJ), on IP protection 16
European Union (EU)
Charter of Fundamental Rights see Charter of Fundamental Rights (EU)
Community exhaustion
placed on market by patent holder or with her consent 147–150
principle of 145–146
territoriality 146–147
downstream purchasers, contractual restrictions on 145–154
on exclusive licensing 100–101, 102
hybrid approach of Commission 127
IP-competition law intersection, development 64–68
negotiations with CARIFORUM states (2008) 284
Index

on non-challenge clauses 98–99
refusal to license in 119–128
access to IPRs 124
Magill, IMS Health, and Microsoft v Commission 121–127, 192
new product, protection 123
two-market requirement 122
value of IPRs 124–125
Volvo and Renault cases 120–121
Regulation No. 240/96 on technology transfer agreements, critique 66–67
as TRIPS Agreement proponent 3
ex post and ex ante approaches, IP protection 15
exclusivity in technology transfer agreements
exclusive dealing 103–104
exclusive licensing 99–102
output restrictions/other non-price restrictions 104–105
exempted clauses, licensing agreements 66
Federal Trade Commission Act (1914), US 59
First Trademark Directive (Directive 89/104/EEC), Article 7 147
FRAND (fair, reasonable and non-discriminatory) terms, patenting technology on 116
FTAIA (Foreign Trade and Antitrust Improvements Act) 1982, enforcement outsourcing 257, 258
GATS (General Agreement on Trade in Services) 1995
Annex on Telecommunications 279
Article III 6
Article IX 261
Article VIII 279
Reference Paper on Basic Telecommunications (Telecoms Reference Paper) 46
Section 1 279, 281
Section 1.2 281
Section 2279, 281
GATT (General Agreement on Tariffs and Trade) 1947
Article VI 196–197
Article X 6
Article XXII 249
Article XXIII.1(b) 52
and origins of WTO 1
Geneva Convention for the Protection of Producers of Phonogram, Vietnam a party to 216
globalization, and technology 161
grantbacks 90–92
‘grey’ clauses, licensing agreements 66
Group of 77, list of forty licensing practices 163
Guatemala
competition statutes 166–167 laissez-faire model 169
Havana Charter for an International Trade Organization (ITO) (1948) 40, 46
Article 46 39
Hegel, Georg Wilhelm Friedrich, theory of IP spirit 13
Hoffmann–La Roche, and compulsory licensing of Tamiflu 234–235, 236
Hong Kong
competition statutes 166–167 laissez-faire model 169
hybrid model, developing countries 174
ICN (International Competition Network), harmonization of competition law, 273–274
incentive thesis, IP protection, 14, 15
India
Competition Act (2002), Section 3.5(i) 167
Competition Commission 168, 171
Monopoly and Restrictive Trade Practices Commission 168
Patent (Amendment) Act (2002), Section 84 168, 171
Patent (Amendment) Act (2005), Section 90(1)(ix) 168, 171
quasi per se prohibition model, following 171
Indonesia
Competition Law (1999), Article 50 167
intellectual property authorities, lack of cooperation with competition authorities 246–247
intellectual property law, in Vietnam 226–230
intellectual property rights see IPRs (intellectual property rights)
International Competition Policy Advisory Committee 273
International Covenant on Economic, Social and Cultural Rights (1966), UN, and property rules of IPRs 13
inventions, patentability of 38
IPRs (intellectual property rights) abuse of 52, 250
and competition law 32–39
dispute settlement 2
economic and legal justifications for 11–18
and economics of innovation 16
ex post justification for IP protection 14
granted to innovators 13
justifications for 15–16
limitations and purpose 23
prevention of abuse 48
property rules and protection of IP 11–24
and technology transfer 24–27
as temporary legal monopoly 18, 32–33
trade and competition, IPR-related 278–280

Jamaica
Fair Competition Act (1993)
Article 3(c) 169–170
Article 20.2(b) 169–170
Article 26.3 169–170
laissez-faire model 169

Japan
Anti-Monopoly Act, Section 21 166
Basic Law on Intellectual Property, Article 10 166
as TRIPS Agreement proponent 3
Vietnam, cooperation with 262

Jefferson, Thomas 12, 14
KFTC (Korea Fair Trade Commission)
Guidelines of Reviewing Undue Exercise of Intellectual Property 166, 167, 172, 173
Microsoft Korea case 176, 177, 177–178
know-how licensing agreements, EC Treaty 66
KPPU (Competition Authority of Indonesia) 167

laissez-faire model, developing countries 169–170
Law on Competition of Vietnam (VLC) see VLC (Law on Competition of Vietnam)
Law on High Technology 2008 (Vietnam) 215
Article 7.2 229
Article 145.1(c) 231
Article 145.1(d) 229
Article 148 229
Article 195.1(b) 231
Article 195.1(c) 229
Law on Pharmaceuticals of Vietnam (2005), Article 9.7 236
Law on Technology Transfer 2006 (Vietnam) 215, 230, 243
Article 17.2 232
Article 20 229
Article 25 229
LDCs (least-developed countries)
competition law and TRIPS Agreement 51
and enforcement outsourcing 257
technology transfer to Members 31
leverage theory, Chicago School 95
lex specialis 118, 219
liability rules, versus property rules 18–24
licensee estoppel doctrine, non-challenge clauses 97
licensing agreements, standard clauses 66–67

Tu Thanh Nguyen - 9781849805445 Downloaded from Elgar Online at 11/11/2021 03:10:30AM via free access
Index

compulsory 51
non-merger arrangements 108–109
as only remedy to end abuse 125
in Philippines 170
remedy of recognized by TRIPS Agreement 44
in Thailand (and reaction to) 199–204, 277
TRIPS Agreement 31, 46–47
in Vietnam 234–236
exclusive 99–102
Notice on Patent Licensing Agreements (1962) 65
tying and package 92–97
Philips' Taiwan Package licensing case 204–212
Locke, John 14
lock-in effects, tying and package licensing 95

Madrid Agreement on International Registration of Marks, Vietnam a party to 215–216

Magill (Radio Telefix Eireann (RTE) and Independent Television Publications Ltd (ITP) v. Commission) 120
and copyright 17
four-factor test 127
IP-competition law intersection, development 65
refusal to license 121–127

Malaysia
Communication and Multimedia Act (1998)
Sections 133–134 174
Sections 133–144 166
Section 136 174
Section 138 174
hybrid model 174
market power, defined 185
MFN (most favoured nation treatment)
IPR-related trade and competition 278
TRIPS Agreement 5, 6, 51
Microsoft tying cases 174–180
anti-competitiveness criterion 176
coelection criterion 176

Microsoft Croatia 179–180, 254, 259
Microsoft Korea 175–178, 180, 254
Microsoft Taiwan 178–179, 180, 254
remedies 177–178
separateness condition 176
three-criterion test, illegality of tying 175–176, 177
misuse doctrine, as defence to patent infringement 61–62

MNCs (multinational corporations)
developing countries, technology transfer in 161–162
and implications for developing countries 291
investigation of for alleged IPR-related anti-competitive practices 247
and protection of IPRs 27
and Vietnam 217
monopolization
antitrust violation, requirements 73
developed countries 71–77
IPRs as temporary legal monopoly 18, 32–33
meaning of ‘monopoly’ 35
moral rights, justifications for IPRs 15
MRFTA (Korean Monopoly Regulation and Fair Trade Act)
Article 3–2(1)(1) 197
Article 3–2(1)(3) 177
Article 3–2(1)(5) 177
Article 23(1)(3) 177
Munich Code (International Antitrust Code), principles 41

NAFTA (North American Free Trade Agreement)
Article 1501.3 41
Article 1704 41
national treatment principle, TRIPS Agreement 5, 6
natural law thesis, IP protection 13, 17
negative comity agreements 264
negative rights of IPRs 18
network effects 72–73
non-challenge clauses, anti-competitive
non-price practices 97–99
normative models, developing countries
hybrid model 174
laissez-faire model 169–170

Tu Thanh Nguyen - 9781849805445
Downloaded from Elgar Online at 11/11/2021 03:10:30AM via free access
quasi per se prohibition model, in developing countries 170–171
simple rule of reason model 172
North American Free Trade Agreement
see NAFTA (North American Free Trade Agreement)
Notice on Patent Licensing Agreements (1962) 65
OECD (Organization for Economic Cooperation and Development)
on absence of competition culture in developing countries 246
Competition Committee 271
Council Recommendation Concerning Effective Action Against Hardcore Cartels 46
harmonization of competition law 271–272
over-enforcement/under-enforcement, TRIPS Agreement 276–278
Paris Convention for the Protection of Industrial Property 2
Article 2.5
Article 5, Section A(2) 171
Article 5.A 274
Article 5.A(2) 41–42
Article 5.A(4) 123, 125
Vietnam a party to 215
passive cooperation agreements 263–264
exclusive licensing 100
reform considered 111–112, 119
Sections
Section 217(d)(4) 106, 108
Section 217(d)(5) 106
Patent Cooperation Treaty (1993), Vietnam a party to 216
patent exhaustion doctrine, contractual restrictions on downstream purchasers 131, 135, 136
patent law
economic rationales for patent system 15–17
international system 38
misuse of patents as antitrust violation 61–62
origins of, in US 60
property rules of IPRs 15
patentability, of inventions 38
per se rule, anti-competitive agreements 69–70
quasi per se prohibition model, in developing countries 170–171
refusal to supply essential facility 183 and tying arrangements 94
US and EU, application by 163 in Vietnam 221, 232
pharmaceutical patents cases, refusal to license (South Africa) anti-retroviral (ARV) medicines 184, 185, 186, 188
application of competition law under pressure of publicity 198
background 180–184
dominant position of a right holder 195–196
efavirenz (EFV) 190, 191
effects of IPR-related competition law application 192–195
essential facility doctrine 182, 183
excessive price 182, 186–187
five-condition test 182–183
IPR-related excessive pricing and refusal to license under competition law 196–198
remedies against anti-competitive pricing and refusal to license 198–199
specific cases Hazel Tau v. GSK & BI 180, 183, 184–188, 189, 192, 195, 197, 198
TAC v. BMS 181, 183, 188, 192, 196
pharmaceuticals and high pharmaceutical prices, exclusive distribution (Vietnam) patents cases, refusal to license 236–238
Philippines Constitution (1987), Section 19, Article XII 170
Section 85 166
Section 87 166, 170
Section 88 166, 170
Section 91 170
Section 93 166, 170
Philips’ Taiwan Package licensing case 204–212
background 204–206
other cases involved 206–210
positive comity agreements 264–265
possessions, IP enjoying protection of 13
Preparatory Committee for the World Economic Conference, study submitted to (1926) 39
pricing, excessive 298–299
productive efficiency, IPRs and competition law 34
property rules IPRs 11–24
enforcement of IPRs under 19–20
land, protection of 22
versus liability rules 18–24
‘side effects’ 21
proportionality test, competition law and TRIPS Agreement 51
public good characteristics of IP 12
Punta del Este Declaration (1986), launch of Uruguay Round 1

Quanta Computer, Inc. v LG Electronics, Inc.
and Federal Circuit judgments 136–145
implications 129–136
prism of 132–136, 142, 145, 150, 154
‘single use only’ restriction 136–137, 138, 139
McFarling II and ‘single crop only’ 140–145
quasi per se prohibition model, in developing countries 170–171
refusal to transfer technology 105–128
refusal to license in EU 119–128
access to IPRs 124
Magill, IMS Health, and Microsoft v Commission 121–127, 192
new product, protection 123
two-market requirement 122
value of IPRs 124–125
Volvo and Renault cases 120–121
refusal to license in US 118

EBay four-factor test 111
eBay Inc and Credit Suisse cases 109–112
Kodak and Xerox cases 114–117
post-Trinko development 109–114
three exceptions to legality of 115
Trinko/traditional views 106–109
US courts of appeals, splits among 114–117
Regulation (EC) No 240/96 on technology transfer agreements, critique 66–67
see also TTBER (Transfer of Technology Block Exemption Regulation) 2004
restrictive practices, concept 164
Revision Conference of The Hague (1925) 42
reward thesis, IP protection 14, 15
Rome Convention (1961) Article 2.5
and TRIPS Agreement 2
royalty concerns (developed countries) 78–86
excessive royalties 78–82
Lemley-Shapiro economic model 81
post-expiration royalties 82–84
total sale royalties 84–86
US and EC, distinguished 81–82
rule of reason, anti-competitive agreements 69, 70–71, 76
abbreviated (truncated or quick look) 70
grantbacks 92
package licensing, application to (Taiwan) 212
pharmaceutical patents cases, refusal to license 183
resale price maintenance in technology transfer 89
simple rule of reason model, developing countries 172–173
and ToT Code 163

Schumpeter, Josef, on dynamic efficiency 34
Set of Multilaterally Agreed Equitable Principles and Rules for the Control of Restrictive Business
Practices, adoption by UN 40, 46, 165
Sherman Act (1890) US
downstream purchasers, contractual restrictions on 136
enforcement outsourcing 257, 258
*per se* violations, licensing practices as 163
Section 1 59, 62, 64, 68, 69, 70, 88, 92, 94, 102
Section 2 59, 62, 64, 71–73, 75, 81–82, 92, 97, 104, 107, 108, 115, 116, 117, 118
Singapore
competition authorities 166
failure of WTO Ministerial Conference in Cancun (2003) 55
simple rule of reason model 172, 173
Smith, Adam 217
Solow, Robert, economic growth theory of 35
South Africa
Competition Commission 187, 192, 198
evaluation of anti-competitive effects (two-step test) 190
pharmaceutical patents cases, refusal to license 180–199
_Hazel Tau v. GSK & BI_ 180, 183, 184–188, 189, 192, 195, 197, 198
_TAC v. BMS_ 181, 183, 188, 192, 196
simple rule of reason model 173
South African Competition Act 1998
pharmaceutical patents cases, refusal to license 181–182
Sections
Section 1.1(ix) 182
Section 1.1(viii) 182
Section 1.1(x) 182, 189
Section 4 173

Section 5 173
Section 7 185, 189
Section 8 173
Section 8(a) 182, 183, 185, 187
Section 8(b) 182–183, 186
Section 8(c) 182, 184, 186, 187, 189
Section 8(d)(ii) 183
Section 10 173
Section 49B(2)(b) 184

Section 56 173
Section 56.2 182
Section 56.2(d) 183
Section 90 173


South Korea
competition authorities 166
Guidelines of the Fair Trade Commission 167, 172, 173
_Microsoft Korea_ tying case 175–178, 180, 254
Monopoly Regulation and Fair Trade Act, Article 59 167
simple rule of reason model 172, 173
see also MRFTA (Korean Monopoly Regulation and Fair Trade Act)
static efficiency, IPRs and competition law 33–34

Supreme Court (US)
on anti-competitive agreements 69
on IP protection 16–17
lower courts having no authority to overrule decisions by 83
on patent law 38
on royalties 78–79

Taiwan
competition authorities 166
Fair Trade Act (2002)
Article 5-1(3) 205
Article 10(2) 205
Article 10(4) 206
Article 14 205, 206
Article 24 212
Article 45 167
Fair Trade Law 179
Guidelines of the Fair Trade Commission 172
Index

technology transfer-oriented provisions 28–32

TRIPS Council
Brazil communication on technical assistance and capacity building (2008) 270
EC communications to 250–251

TT (Technology Transfer) Guidelines (EU)
exclusive dealing 103, 105
exclusive licensing 101
grantbacks 92
and modernization of EU competition law 67, 68
non-challenge clauses 99
royalty concerns 78
tying and package licensing 95, 96–97

TTBER (Transfer of Technology Block Exemption Regulation) 2004

Articles

Article 1.1(b) 67
Article 3 68
Article 4.1 67, 68
Article 4.1(a) 89
Article 4.1(c) 151
Article 4.2 67, 68
Article 4.2(2) 89
Article 4.2(b) 151
Article 5 67
Article 5.1 68
Article 5.1(a) 92
Article 5.1(b) 92
Article 5.1(c) 99
Article 5.2 68

convergence between US and EC competition policies 159
developing countries, current models 166
and modernization of EU competition law 67, 68
non-challenge clauses 99
Preamble 71
restriction of competing party’s ability to determine prices 89
restrictions on licensees exempted 151
and Singapore Competition Commission Guidelines 172

software copyright licensing, extension to cover 67
tying and package licensing 92–97
contractual tying/technological tying 93
definitions 92–93
lock-in effects 95
Microsoft tying cases
Microsoft Croatia 179–180, 254, 259
Microsoft Korea 175–178, 180, 254
Microsoft Taiwan 178–179, 180, 254

offensive and defensive tying 97
pro-competitive benefits of tying 94
tyting of IPR-unrelated products to use of IPR-incorporated products 60

UNCTAD (United Nations Conference on Trade and Development)
harmonization of competition law 272–273
and ToT Code 40, 162
and Vietnam 217
undertaking/association of undertakings 218, 219
Unilateral Conduct Working Group (ICN) 274
United Nations (UN)
Declaration on the Establishment of a New International Order 161
New International Economic Order, principles for (1974) 162
Set of Multilaterally Agreed Equitable Principles and Rules for the Control of Restrictive Business Practices, adopted by 40, 46, 165
UNCTAD see UNCTAD (United Nations Conference on Trade and Development)

United States
antitrust law see antitrust and IP law, US
Argentina-US mutually agreed solutions 247–250

Charming Betsy doctrine 11
Clayton Act see Clayton Act (1914), US
Congress, Office of Technological Assessment 4
Constitution, Article 1, Section 8, Clause 8 13, 17, 112
development of IP-antitrust law
intersection in 59–64
downstream purchasers, contractual restrictions on 129–145
Federal Trade Commission Act see Federal Trade Commission Act (1914) US
patent law 60
refusal to license in 106–119
eBay Inc and Credit Suisse cases 109–112
Kodak and Xerox cases 114–117
post-Trinko development 109–114
two exceptions to legality of 115
Trinko/traditional views 106–109
US courts of appeals, splits among 114–117
Sherman Act see Sherman Act (1890), US
Supreme Court see Supreme Court (US)
trade sanctions threatened by 164–165
as TRIPS Agreement proponent 3
US–Korea FTA
Article 11.6(2) 253
Article 11.6(5) 253
US–Vietnam Agreement on Trade Relations, Article 10.1 253
WTO law, direct effect not recognized in domestic legal system 9
Universal Declaration of Human Rights, UN (1948), Article 27 13
Uruguay Round (1986–1994) 1, 4
negotiations 9, 164
Uruguay Round Agreements Act 1994
Section 102(a)(1) 8
Section 102(c)(1) 8
VBL (Vietnam Brewery Ltd),
competition case 238–242
VCAD (Competition Administration Department), Vietnam 219, 241
vertical agreements, Vietnam 221
Article 26 7
Article 27 7, 282
Vietnam
appellations of origin (Civil Code) 214
background to technology transfer/competition law
212–226
Civil Code 1995 217, 226
Article 47 214
Article 188 214
Article 786 214
Article 802 235
Article 809 227
Article 810 227
Article 813 228
Civil Code 2005 215, 217
competition law 216–226
abuse of a dominant position/monopoly position 223–226
anti-competitive agreements/concerted practices 219–223
market power presumption 231
refusal to deal 231
technology transfer-related 230–233
Constitution 217
Article 2 213
Article 12 213
Article 15 213
Article 21 213
Article 57 213
Article 58 213
Decree 48/1998/ND-CP
Article 13 228
Article 15 227
Article 23 228
Article 32 227
prohibited conditions 228
economy 212
as example of deficiency of competition legislation 245
intellectual property law 214–216

Tu Thanh Nguyen - 9781849805445
Downloaded from Elgar Online at 11/11/2021 03:10:30AM
via free access
Vietnam a member of Working Group on the Intersection between Trade and Competition Policy.

Members, moral rights, not obligated to protect.

Zuellig Pharma (ZPV), Vietnam.

Competition law, technology transfer and the TRIPS Agreement.